Alimera Sciences has granted Ocumension Therapeutics an exclusive license agreement to develop and commercialize Iluvien in Greater China and other Western Pacific countries, according to a press release.
Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) will have a distinct trademark in these areas under Ocumension. Alimera received a $10 million upfront payment and may receive up to $89 million in sales-based milestone payments, the release said.
In addition, Ocumension made a $10 million equity investment in Alimera through a private offering of 1,144,945 shares of Alimera’s